Share this article
Round led by Claris Ventures with 2Invest, 3B Future Health Fund and Astellas Venture Management
CAMBRIDGE, England, March 9, 2021 /PRNewswire/ NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces the close of a £15.2m (US $21m) Series B round. The syndicate was led by Claris Ventures and included 2Invest, 3B Future Health Fund and Astellas Venture Management alongside founding investor the CRT Pioneer Fund.
NeoPhore is focused on the discovery and development of novel first-in-class small molecule drugs targeting the DNA mismatch repair (MMR) pathway to treat cancer. NeoPhore will work closely with its scientific founder Dr Alberto Bardelli from the University of Turin where the original scientific discovery originated and Dr Luis Diaz (Memorial Sloan Kettering and SAB member) to exploit the concept that inhibition of MMR in tumours generates neoantigens that the patients own immune system can target with a powerful a
NeoPhore Announces £15 2m Financing to Advance DNA Mismatch Repair Pipeline
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Catamaran Bio Announces Appointment of Dr Alvin Shih as President and Chief Executive Officer
financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Catamaran Bio Announces Appointment of Dr. Alvin Shih as President and Chief Executive Officer
February 4, 2021 GMT
Catamaran CEO Alvin Shih (Photo: Business Wire)
CAMBRIDGE, Mass. (BUSINESS WIRE) Feb 4, 2021
Catamaran Bio, Inc., a biotechnology company developing allogeneic CAR-NK cell therapies to treat diseases with significant unmet medical need, today announced the appointment of Alvin Shih, MD, MBA, as President and Chief Executive Officer. He has concurrently been appointed to the Board of Directors for Catamaran. Dr. Shih is an experienced biopharma executive with a track record of success in building companies across a broad spectrum of disease areas and therapeutic modalities, including cell and tissue therapies.
December 21, 2020
December 21, 2020 | Funding updates around the life sciences including cash for a handheld mass spec device, Series D for oncolytic immunotherapy, a new company launch in allogenic CAR-NK cells, AI-powered cell classification, a 3-D sequencing platform, and more.
$170M: Israeli ‘Digital Health First’ VC Firm
OTV (formerly Olive Tree Ventures), Israel’s ‘digital health first’ venture capital firm, today announced the closing of a fund with a total value of $170M. OTV also announced their new name and the appointment of a new Head of Asia Pacific to spearhead the fund’s expansion into the region’s market. OTV is the only venture capital fund in Israel whose primary focus is digital health, specializing in supporting their portfolio companies reach maturity, refine execution, tackle regulatory hurdles and ensure a global imprint on validated products. Over the course of the past five years, OTV has prioritized investment in digital health